Lewis Drug launches First Stop Pharmacy Club
SIOUX FALLS, S.D. Lewis Drug recently launched a new generics prescription drug program called the First Stop Pharmacy Club, according to a report in the Sioux Falls daily, the Argus Leader, published Friday.
The program, which costs $10 to join, includes as many as 400 generic prescription drugs available for $4 for a 30-day supply. Other features of the Pharmacy Club program include discounts on everyday basics such as milk and bread and a $10 Lewis coupon when you sign up.
“We are trying to help the community fight pricing on generic drugs and work with suppliers in trying to negotiate better pricing and pass that on to consumers,” Bob Meyer, Lewis Drug merchandise manager, told Argus Leader. “In a tough economy, we are trying to give back to the community which has supported us for more than 60 years.”
Customers that are enrolled in a publicly funded health program such as Medicare, Medicaid and TRICARE are not eligible to participate in Club benefits pertaining to discounts on prescription drugs, the company states on its web site.
NOCA recognizes PTCB’s Corrigan with Certification Industry Leadership Award
WASHINGTON Melissa Murer Corrigan, executive director and chief executive officer of the Pharmacy Technician Certification Board, has received the 2008 Certification Industry Leadership Award from the National Organization for Competency Assurance, PTCB announced Tuesday.
PTCB said the award recognized Murer Corrigan’s leadership in the field of certification and licensure. She has certified more than 320,000 pharmacy technicians as the founding executive of PTCB.
“This award is a tribute to the hard work and dedication of all my colleagues and partners involved in making PTCB a success since our founding in 1995,” Murer Corrigan said in a statement. “The certification of pharmacy technicians in the U.S. has advanced the patient safety of millions of Americans, and I am so proud of the PTCB team and all of our certified technicians.”
FDA warns Shionogi to end unsupported Cedax claims
ROCKVILLE, Md. The Food and Drug Administration released a warning letter to Shionogi and Co. Tuesday regarding its antibiotic Cedax.
The FDA said the company made inflated claims about Cedax (ceftibuten) and downplayed the health risks associated with it. Promotional materials sent to doctors claimed the drug had “excellent tolerability,” even though data did not support the claim.
The drug is approved for treating mild to moderate bacterial infections.